All News

Patients with resected non-small cell lung cancer (NSCLC) are at risk for recurrence of disease, but currently there are no tools to predict which patients are at highest risk. The authors set out to create a risk model incorporating both clinical data and biomarkers.

The Senate approved a bill Monday evening that prevents steep cuts to Medicare physician payments from going into effect for one year and delays the conversion to ICD-10 diagnostic and procedure codes for at least one year.

The public will learn for the first time this fall exactly how much their doctors are paid by the drug companies and devicemakers whose products they use. But don't expect it to be the end of the inquiry.

Rates of new cancer cases in the United States have fallen slightly in recent years, according to a new report from the Centers for Disease Control and Prevention.

The Medicare Payment Advisory Commission (MedPAC) recently aired concerns as to whether the patient-centered medical home (PCMH) can serve as a model for providing value-based care. In particular, several members asserted that the medical home model may have a real cost disadvantage for health systems. They explained that without evidence-based research, it is difficult to determine if the model encourages practices to use their cost savings to improve care.

A new oral angiogenesis inhibitor for the treatment of lung cancer could be edging closer to the market: Approval application for nintedanib (Boehringer Ingelheim) has been filed in Europe and is being prepared for the United States.

Groundbreaking hepatitis C therapies represent a new era in treatment. But their cost is unprecedented, meaning health plans and PBMs are facing difficult formulary decisions.

As the FDA expedites approval of novel therapies, plans will need strategies to provide appropriate access while remaining observant of potential adverse events.

Healthcare spending rose at the fastest pace in 10 years last quarter, a development that could foreshadow higher costs for consumers this year.

Doctors are trying to stoke a rebellion against the doc fix.

As the quality and cost transparency movements gain support within the healthcare industry, a more important question persists: what will actually work for consumers?

The National Comprehensive Cancer Network® (NCCN) will host Designing Clinical Trials in the Era of Multiple Biomarkers and Targeted Therapies on April 25, 2014 in Bethesda, Maryland, as part of the NCCN Oncology Policy Program.

A panel of Food and Drug Administration advisers has voted to endorse an experimental stool test that uses DNA to detect colon cancer and precancerous growths.

Results of a phase II trial of the PARP inhibitor olaparib, presented at the meeting of the Society of Gynecologic Oncology, showed that maintenance therapy with olaparib significantly improved PFS in ovarian cancer patients.

Drug development is a risky business, with an estimated 90 percent of compounds that enter clinical trials ultimately failing to reach the market.

The House of Representatives passed a controversial bill that will extend the sustainable growth rate (SGR) formula for physician payments for 1 year.

AstraZeneca's Phase III pipeline is growing ahead of plan, chief executive Pascal Soriot told a recent media briefing, and cancer drugs make up a major chunk of the pipeline.

The Centers for Medicare & Medicaid Services' proposal to mandate broader provider networks in public insurance exchanges could have the unintended consequence of discouraging insurer participation, according to analysts at Moody's.

The effectiveness of radiation treatments for patients with squamous cell cancer of the head and neck has been reviewed by an international team of researchers. They identified two biomarkers that were good at predicting a patient's resistance to radiation therapy. "While our findings are encouraging, and a step toward personalized medicine, we hope to do more of this research with a larger, randomized trial," the authors conclude.

Ceritinib, which received a 'breakthrough therapy' status from the FDA last year, was highly active in patients with advanced, ALK-rearranged NSCLC, including those who had had disease progression during crizotinib treatment, regardless of the presence of resistance mutations in ALK.

Health information technology (HIT) system advancements, including medical device improvements, could account for more than $30 billion per year in savings.

Despite opposition from doctors' groups, on a voice vote Thursday, the House of Representatives passed a one-year patch for Medicare's unpopular sustainable growth-rate formula for physician payments and, in the same bill, extended the implementation deadline for ICD-10 diagnostic and procedural codes for at least a year.

Enrollment of Phase 3 study in first-line advanced liver cancer is expected to begin by mid-2015. The companies also plan to initiate several additional Phase 1/2 trials for different cancers during 2014.

In the treatment of lung cancer, immunotherapy has come of age and is here to stay expert says at the 4th European Lung Cancer Conference.

Facing heavy bipartisan opposition on Capitol Hill as well as from patient groups, businesses, insurers and others, the Centers for Medicare & Medicaid Services said Monday it did not plan to move ahead at this time with several proposed changes to the Medicare prescription drug program.

The House Ways and Means bill to temporarily prevent Medicare physician payment cuts also would deliver an Easter gift to hospitals-a six-month extension to comply with a controversial new inpatient payment rule for hospitals.

The bundled payment model encourages health systems to provide high quality, better-coordinated care at a lower cost for Medicare beneficiaries. It's no wonder, then, why the American Gastroenterological Association (AGA) has developed a colonoscopy bundled payment model to help gastroenterologists achieve value-based health outcomes.

Another temporary 12-month patch will be enacted for the doc fix prior to the scheduled March 31 expiration of the current patch, House Speaker John Boehner (R-Ohio) indicated Wednesday.

With a new study of Independence Blue Cross members, evidence on the effectiveness of the patient-centered medical home is swinging back towards the positive.

With less than a week remaining to sign up for private health insurance under the Patient Protection and Affordable Care Act, more than half of the uninsured don't know that March 31 is the deadline.